Dustin Schaefer

• Advised Collegium Pharmaceuticals on its acquisition of AZSTARYS from Corium Therapeutics for $650 million with the potential for additional milestone payments up to $135 million.
• Advised Hospital for Special Surgery and General Atlantic in its acquisition of Legent Health, a leading operator of orthopedic and spine facilities. 
• Advised YourBio Health, Inc., a pioneer in capillary whole blood sampling technology, on its sale to Hims & Hers Health, Inc.
• Advised a healthcare data and CRO company in its $750 million acquisition of an end-to-end value-based care technology platform. 
• Advised an integrated digital health and pharmacy services company in its acquisition of a leading digitally-powered specialty pharmacy in a transaction valued at over $1 billion.
• Advised Great Hill Partners and its affiliated investment funds in its investments in Blue Cloud Pediatric Surgery Centers and Intuitive Health.
• Advised Boston Scientific on its acquisition of EluPro™ and CanGaroo® bioenvelopes from Elutia Inc. for $88 million.
• Advised 65 Equity Partners in its investment in Allied OMS, a doctor-led management services organization supporting oral and maxillofacial surgery practices.
• Advised InTandem Capital Partners, LLC, and its affiliated investment funds and portfolio companies in connection with its majority investments in and/or add-on acquisitions in its oral surgery, orthopedic surgery and contract research organization investments.
• Advises leading venture capital and growth equity funds on portfolio company investments across a broad range of high-growth life sciences, healthcare, and technology companies.
• Advised Gentiva, a dedicated hospice, palliative, and personal care company, in its $710 million asset purchase of hospice and home care assets from ProMedica.*
• Advised Pfizer Inc. in its acquisition of Biohaven Pharmaceutical, a transaction valued at approximately $11.6 billion.* 
• Advised global alternative asset management firm TPG in its $4 billion take-private acquisition of Covetrus, a global leader in animal-health technology and services.*
• Advised dialysis provider US Renal Care, Inc. in its affiliation with Satellite Healthcare, Inc.*
• Advised The Vistria Group and its affiliated investment funds in their co-investment in PANTHERx Rare Pharmacy, a specialty pharmacy focused on orphan drugs and rare diseases, in a transaction valued at $2.8 billion.*
• Advised TSG Consumer Partners in its co-investment in Specialty Dental Brands, a leading dental support organization.*
• Advised a leading private equity firm in platform and add-on acquisitions for two portfolio companies: a leading provider of on-site clinical services to long-term care facilities, and a network of urgent care clinics in New England.*
• Advised ConvaTec Inc. in its acquisition of Triad Life Sciences Inc. for $125 million with the potential for additional milestone payments up to $325 million.*
• Advised a leading private equity firm in its acquisition of a primary care platform focused on Medicare Advantage patients in Central and South Florida.
• Advised a leading medical device company in its acquisition of an artificial intelligence-enabled platform for real-time monitoring of surgical blood loss for $160 million.*
• Advised a leading private equity firm in various acquisitions for one of the nation's largest healthcare staffing platforms.*
• Advised a leading private equity firm in its investment in an independent third-party administrator of healthcare benefits for self-funded employers, covering over 400,000 lives.*
• Advised Welsh Carson Anderson & Stowe and its portfolio company US Radiology Specialists in its add-on acquisition of Windsong Radiology.* 
• Advised Aquiline Capital Partners LLC in its investment in National Medical Billing Services.*
• Advised The Jackson Laboratory, a US-based nonprofit biomedical research institution, in its acquisition of Charles River Laboratories Japan’s Research Models & Services.*
• Advised Rutgers University in negotiating its Integrated Practice Agreement with RWJBarnabas Health, creating one of the largest integrated health systems in the country.*
• Advised Renown Health in connection with their nursing school affiliation with Reno School of Medicine.*

*Indicates experience prior to joining Goodwin.

• Advises clients on complex regulatory issues, including those related to the Stark Law, Anti-Kickback Statute, False Claims Act, Civil Monetary Penalties Law, Medicare and Medicaid participation, corporate practice of medicine, the federal Controlled Substances Act, HIPAA, and issues involving clinical research.
• Advises clients on compliance risk assessments, programs, and policies.
• Advises on reimbursement matters, including Medicare and Medicaid conditions of participation, commercial payor coverage and credentialing, and responses to third-party payor repayment demands.
• Advises various pharmaceutical and medical device companies on fraud and abuse matters, including with respect to their customer discount and rebate arrangements, HUB service offerings, sales and marketing arrangements, clinical research issues, and compliance program requirements.
• Assisted a medical device manufacturer in obtaining a favorable Advisory Opinion from the U.S. Department of Health and Human Services Office of Inspector General in connection with a Category B Investigational Device Exemption study.
• Advised various third-party payors, including leading private insurers, Medicare Advantage Organizations, Medicaid Managed Care Organizations, and third-party administrators on various contractual arrangements and compliance matters including with respect to Medicare Advantage risk adjustment, Medicare marketing guidelines, license requirements, and applicable state law requirements.*
• Negotiated various value-based care and risk-sharing payment arrangements on behalf of healthcare providers and health technology companies.*
• Assisted a PACE Organization in connection with strategic joint ventures and counseled on applicable state law requirements.*
• Advised academic medical centers on issues related to compliance with Medicare conditions of participation, accreditation requirements, and obligations under academic affiliation agreements.*
• Advised leading global pharmaceutical companies on structuring patient assistance programs in compliance with state fraud and abuse restrictions.*

*Indicates experience prior to joining Goodwin.

• Represented a clinical laboratory in a voluntary self-disclosure to the U.S. Department of Health and Human Services Office of Inspector General regarding overpayments in connection with deficient billing and coding practices.
• Represented a global medical device company in an internal investigation in connection with a Department of Justice Civil Investigative Demand.
• Conducted numerous internal investigations in response to whistleblower reports and other compliance-related concerns.